(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 February 2007 (01.02.2007)

PCT

(10) International Publication Number
WO 2007/014278 A3

(51) International Patent Classification:
A61K 39/395 (2006.01) *C12N 15/13* (2006.01)
C07K 16/28 (2006.01) *C12N 15/85* (2006.01)
A61P 35/00 (2006.01) *C12N 5/10* (2006.01)
A61P 37/00 (2006.01) *C07K 16/46* (2006.01)
A61P 21/04 (2006.01)

(21) International Application Number:
PCT/US2006/029038

(22) International Filing Date: 25 July 2006 (25.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/702,499 25 July 2005 (25.07.2005) US
60/800,595 16 May 2006 (16.05.2006) US

(71) Applicant *(for all designated States except US)*: **TRUBION PHARMACEUTICALS** [US/US]; 2401 Fourth Avenue, Suite 1050, Seattle, WA 98121 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GROSMAIRE, Laura, Sue** [US/US]; P.O. Box 252, Hobart, WA 98025 (US). **HAYDEN-LEDBETTER, Martha, Susan** [US/US]; 18798 Ridgefield Road NW, Shoreline, WA 98178 (US). **LEDBETTER, Jeffrey, A.** [US/US]; 18798 Ridgefield Road NW, Shoreline, WA 98177 (US). **THOMPSON, Peter, Armstrong** [US/US]; 14075 30th Place N.E., Bellevue, WA 98007 (US). **SIMON, Sandy, Alexander** [US/US]; 1904 NE 68th Street, Seattle, WA 98115 (US). **BRADY, William** [US/US]; 618 219th Place SW, Bothell, WA 98021 (US).

(74) Agent: **JANULIS, Lynn, L.**; MARSHALL, GERSTEIN & BORUN, 233 S. Wacker Drive, Suite 6300, Sears Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
30 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES

(57) Abstract: The present application generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The application further provides materials and methods for application treatment of diseases involving aberrant B-cell activity. In addition, the application provides humanized CD37-specific binding molecules.

WO 2007/014278 A3